We are offering a broad technology platform capable of producing novel amorphous solid states of pharmaceutical actives in conjunction with stabilizing excipients. Finished products are obtained as dry amorphous micron to nanosized powders. The main applications of our technology platform are the generation of physically and chemically amorphous solid states and the generation of micro- and nanoparticles for pharmaceutical actives. Uses for the application include all commonly employed solid dosage forms, e.g. oral, pulmonary or parenteral. Benefits of amorphous solid states include foremost the generation of new intellectual property, additionally enhancing existing routes of drug delivery and enabling targeted drug delivery, thereby creating added value. Potential barriers due to distinct properties of crystalline dosage forms can be overcome. Uses for amorphous solid states in either life-cycle management or accelerating generic competition can be envisaged. Worldwide dozens of potential drug targets exist which would benefit from our amorphization approach, with sales in total exceeding 50 B$.

To access the rest of the information on this page,
Log In or sign up for a free B-Bridge account: